誘発性静脈血栓塞栓症の延長治療のためのアピキサバン
Gregory Piazza1,2, Behnood Bikdeli1,2,3, Arvind K Pandey2
1Thrombosis Research Group, Brigham and Women's Hospital-Harvard Medical School, Boston.
The New England journal of medicine
|September 1, 2025
まとめ
アピキサバンによる延長抗凝固療法により,誘発性静脈血栓塞栓症 (VTE) と継続的なリスク因子を持つ患者で,再発性静脈血栓塞栓症 (VTE) が著しく減少しました. この治療は重度の出血のリスクが低いことを示した.
科学分野:
- 心臓病科
- 血液学
- 臨床試験
背景:
- 静脈血栓塞栓症 (VTE) の抗凝固薬の最適な持続時間については,一時的な誘発因子と持続的なリスク因子を持つ患者について不確実性があります.
- 誘発されたVTEの場合,再発リスクと出血合併症のバランスを取るために慎重に管理する必要があります.
研究 の 目的:
- 誘発されたVTEと持続的な危険因子を持つ患者の再発性VTEを予防するための長期間のアピキサバン療法の有効性と安全性を評価する.
- アピキサバン群とプラセボ群の間で,症状的な再発性VTEと重度の出血のリスクを比較する.
主な方法:
- 単一センター,ダブルブラインド,ランダム化試験で,一時的な誘発因子と少なくとも1つの永続的なリスク因子によりVTEを患った600人の成人を対象とした.
- 参加者は,最初の3ヶ月の抗凝固期間の後に12ヶ月間,経口アピキサバン (2. 5 mg,毎日2回) またはプラセボを投与された.
- 主なアウトカムには,国際血栓症および血液静止学協会の基準で定義された症状的な再発性VTEおよび主要な出血事件が含まれていました.
主要な成果:
- プラセボ群の10. 0%に対して,アピキサバン群の1. 3%の患者で再発性VTEが発生した (リスク比0. 13;P< 0. 001).
- アピキサバン投与を受けた1人の患者で,プラセボ投与を受けた患者はいなかった. 臨床的に重要な非重度の出血はアピキサバンでより頻繁であった (4. 8% 対 1. 7%).
- どちらのグループでも心臓血管や出血による死亡は認められませんでした.
結論:
- 12ヶ月間の低強度アピキサバン療法は,誘発されたVTEと持続するリスク因子を持つ患者の症状的な再発性VTEのリスクを有意に低下させた.
- 大量出血の低リスクは,この患者集団におけるアピキサバン治療の延長を支持する.
- HI-PRO試験 (NCT04168203) の結果は,VTE管理における抗凝固戦略を最適化するための貴重な証拠を提供します.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251


